![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sun Pharma’s Deuruxolitinib IND Placed on Partial Clinical Hold
Sun Pharma’s Deuruxolitinib IND Placed on Partial Clinical Hold
The FDA has placed a partial clinical hold on Sun Pharma’s IND application for Deuruxolitinib (CTP-543), which was being studied in patients with alopecia areata, an autoimmune disease that includes hair loss.
The agency decision follows the report of a serious adverse event of pulmonary embolism occurring at the 12 mg twice a day dose in one of the long-term open label extension studies.
Despite the serious adverse event, the company said that no thromboembolic events occurred in phase 2 and phase 3 clinical trials and that it will work with the FDA to address the agency’s concerns, which will be expressed in a formal letter, to be received by Sun Pharma within the next 30 days.
Related Topics
Upcoming Events
-
21Oct